A PHASE IB-II STUDY OF HIGH-DOSE POST-TRANSPLANT CYCLOPHOSPHAMIDE BORTEZOMIB ABATACEPT AND SHORT-DURATION TACROLIMUS FOR THE PREVENTION OF GRAFT-VERSUS-HOST DISEASE (GVHD) FOLLOWING HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT)
Are you eligible to participate in this study?
You may be eligible for this study if you meet the following criteria:
-
Conditions: Graft-versus-host Disease
-
Age: Between 18 years - 100 years
-
Gender: Male or Female
-
Other Inclusion Criteria:
1) Karnofsky score 70%. >> 2) No evidence of progressive bacterial, viral, or fungal infection. >> 3) Creatinine clearance > 50 mL/min/1.72m2.
You may not be eligible for this study if the following are true:
-
1) Donors are excluded in case of donor-specific HLA antibodies or positive cross-match. > 2) Patient had myocardial infarction within 6 months prior to enrollment or has New York Heart Association (NYHA) Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities.
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
